🔗 Share this article WHO Raises Concern Over Acute Lack of Weight-Loss Injections Fewer than 10% of individuals who could benefit from obesity jabs including Wegovy have access to them, states the WHO as it releases its initial recommendations on the therapies. Given more than one billion individuals worldwide currently classified as obese, it is calling for more widespread and fairer access to this class of drugs. Per forecasts, over two billion will be obese by 2030 unless action is taken. "Our new guidelines affirms that excess weight is a chronic disease that can be treated with comprehensive and lifelong care," stated WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and logistical bottlenecks are key barriers to widespread access to the jabs that can aid individuals in losing substantial body mass, says the agency. Weight-Loss Drug Supply Crisis Despite the current most optimistic outlook, the manufacturing of these medications would only suffice for approximately 100 million people – less than 10% of those who need them, according to the WHO. The advice calls on governments and firms to increase availability, through strategies such as licensing agreements. Exclusive production rights on a key compound – the core ingredient of the drug Wegovy – is scheduled to end in several countries in 2026. The Way Obesity Jabs Function These medications replicate a body's own hormone to reduce digestion speed, suppress the appetite and boost feelings of fullness so individuals reduce food intake. Patients typically begin shedding pounds after several weeks of starting on the regular doses. Evidence suggests users may regain a significant portion a year later of stopping the medication, when their usual appetite come back. To be above a healthy weight raises your likelihood for experiencing diseases, such as diabetes, cardiovascular issues, stroke, and certain cancers. Excess weight affects people in all nations and was responsible for 3.7 million deaths worldwide in 2024, as per the WHO.
Fewer than 10% of individuals who could benefit from obesity jabs including Wegovy have access to them, states the WHO as it releases its initial recommendations on the therapies. Given more than one billion individuals worldwide currently classified as obese, it is calling for more widespread and fairer access to this class of drugs. Per forecasts, over two billion will be obese by 2030 unless action is taken. "Our new guidelines affirms that excess weight is a chronic disease that can be treated with comprehensive and lifelong care," stated WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and logistical bottlenecks are key barriers to widespread access to the jabs that can aid individuals in losing substantial body mass, says the agency. Weight-Loss Drug Supply Crisis Despite the current most optimistic outlook, the manufacturing of these medications would only suffice for approximately 100 million people – less than 10% of those who need them, according to the WHO. The advice calls on governments and firms to increase availability, through strategies such as licensing agreements. Exclusive production rights on a key compound – the core ingredient of the drug Wegovy – is scheduled to end in several countries in 2026. The Way Obesity Jabs Function These medications replicate a body's own hormone to reduce digestion speed, suppress the appetite and boost feelings of fullness so individuals reduce food intake. Patients typically begin shedding pounds after several weeks of starting on the regular doses. Evidence suggests users may regain a significant portion a year later of stopping the medication, when their usual appetite come back. To be above a healthy weight raises your likelihood for experiencing diseases, such as diabetes, cardiovascular issues, stroke, and certain cancers. Excess weight affects people in all nations and was responsible for 3.7 million deaths worldwide in 2024, as per the WHO.